Several medications such as baclofen, amitriptyline and even antiepileptic drugs such as carbamazepine or vigabatrin are known to induce absence status epilepticus in patients with generalized epilepsies. Tiagabine (TGB) is effective in patients with focal epilepsies. However, TGB has also been reported to induce non-convulsive status epilepticus in several patients with focal epilepsies and in one patient with juvenile myoclonic epilepsy. In animal models of generalized epilepsy, TGB induces absence status with 3-5 Hz spike-wave complexes.
INTRODUCTION
Absence status epilepticus is defined as a generalized absence seizure lasting for more than half an hour in the context of a primary generalized epilepsy 1 . During the time of mental clouding of differing degree, bilateral synchronous spike-wave discharges can be recorded by EEG. Of all the forms of non-convulsive status epilepticus, generalized absence status is the most commonly encountered 2 . The incidence of absence status in patients with absence epilepsy is estimated to be between 2 and 10% 3 .
Several antiepileptic drugs have been reported to induce absence status in patients and animal models. Tiagabine (TGB) inhibits the reuptake of γ -aminobutyric acid (GABA) into the presynaptic terminals and glia cells, thereby making more GABA available at the synapses 4 . It increases the extracellular concentration of GABA after oral administration 5, 6 . In clinical trials TGB had a dose-related anticonvulsant effect in patients with focal epilepsies [7] [8] [9] [10] [11] . However, in animal models the frequency of interictal spike- * E-mail: knake@mailer.uni-marburg.de wave discharges increased in rats when treated with TGB [12] [13] [14] .
In addition, TGB was also reported to induce nonconvulsive status epilepticus in several patients with partial epilepsy 15, 16 and in one patient with juvenile myoclonic epilepsy 6 . There have been no detailed reports of this effect of TGB in patients with absence epilepsy.
We describe a 32-year-old patient with absence epilepsy and generalized tonic-clonic seizures since the age of 11 years, in whom TGB induced her first absence status.
CASE REPORT
A 32-year-old woman was admitted with absence status epilepticus lasting for more than 6 hours.
At the age of 11 years, she began having absences and generalized tonic-clonic seizures. The diagnosis of absence epilepsy was supported by generalized spike-wave complexes during hyperventilation and a positive family history for epilepsy. Seizures were refractory to valproate, primidone, lamotrigine, and clonazepam as monotherapy and in several combinations. Initially, she had two to three absences per week and one generalized tonic-clonic seizure every two months. She has not experienced any absence seizures and the frequency of generalized tonic-clonic seizures declined to two per year since she was started on anticonvulsants.
Lamotrigine was discontinued due to nausea and TGB was added to sodium valproate by her neurologist. The dosage of valproate remained unchanged. Routine EEGs were normal except for short bursts of generalized spike-wave discharges under hyperventilation.
In the first 6 months, up to a daily dosage of 30 mg, the patient tolerated the new medication well and was seizure-free except for one generalized tonic-clonic seizure shortly after initiation of TGB therapy. Therefore, the dose of TGB was increased to 45 mg/d at the next follow-up visit. Within days, the patient repeatedly started to feel dizzy and experienced episodes of 'lack of memory'. At this time, the EEG revealed intermittent generalized slowing and spike-wave complexes during 30% of the recording.
On admission, the patient was treated with 2400 mg valproate and 45 mg TGB. The serum level of valproate was 74 mg/l. She was admitted for an episode lasting for more than 6 hours, during which she stared and reacted slowly. She was unable to do simple calculations (e.g. 3 × 3) but was fully oriented. She responded slowly but adequately to other questions. Within the previous 5 days before admission, she had three similar episodes with mental clouding lasting more than 4 hours each. She had never experienced absences lasting for more than a minute before treatment with TGB.
The EEG on admission revealed absence status epilepticus ( Fig. 1) with generalized spike-wave complexes. Initially, she was given 600 mg of sodiumvalproate intravenously to booster the levels, however, without any effect. After administration of 1 mg lorazepam, the EEG and the clinical picture rapidly normalized.
Tiagabine was discontinued because a status epilepticus inducing effect was suspected. The EEG remained normal thereafter. The patient was discharged on 2400 mg of sodium valproate. No further status epilepticus occurred on follow-up 6 months later.
DISCUSSION
We report a patient with generalized epilepsy who developed EEG deterioration and her first absence status epilepticus while taking TGB. Besides the temporal relation and the complete EEG normalization after discontinuation of TGB, several additional lines of evidence support that TGB induced the status epilepticus in this patient and suggest a GABA-ergic mechanism.
Observations in humans
TGB was reported to induce non-convulsive status epilepticus in several patients with focal epilepsies and in one patient with juvenile myoclonic epilepsy 6, [15] [16] [17] . Other GABA-ergic medications such as baclofen or vigabatrin [18] [19] [20] [21] [22] have been reported to induce absence status epilepticus in humans.
Animal data
In several animal models of absence epilepsy (i.e. a selective strain of Wistar rats (WAG/Rij-rats) or genetic absence epilepsy rats of Strasbourg (GAERS)), proabsence effects of vigabatrin and TGB have been demonstrated 6, 12, 23 . After administration, TGB enhanced the duration and the number of spike-wave discharges in a dose-related fashion 12 . Furthermore, an unusual second type of spike-wave discharges was recorded during the treatment with TGB. These were considered to be forerunners of the genuine spike-wave discharges 13 . At a higher TGB dosage, seven of 10 normal animals developed behavioural hyporeactivity and simultaneously generalized 3-5 Hz spike-wave discharges 6 .
GABA plays an important role in the pathophysiology of absence seizures. The application of other GABA-ergic drugs such as vigabatrin, an irreversible inhibitor of the GABA-transaminase, or baclofen, a GABA-agonist, to genetically absence-prone rats also lead to an exacerbation of absence seizures and a dose-related increase in spike-wave discharges 22 . The synchronous spike-wave discharges during absence seizures are generated by thalamo-cortical circuits between the reticular thalamic nucleus and thalamic relay neurons as well as neocortical pyramidal cells. This circuit is mediated by influences on the GABA B and GABA A -receptors 24, 25 . An excessive stimulation of these structures induces absence seizures 24, 26 .
In conclusion, TGB, a GABA-reuptake inhibitor, can induce absences and absence status in patients with absence epilepsy. This effect appears to be mediated by a GABA-ergic mechanism. Therefore, tiagabine should be used cautiously in the treatment of generalized epilepsies. The EEG can be useful in detecting an increased frequency of spike-wave complexes after elevating the tiagabine dose.
